Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasm, Residual 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

nilotinib 4Cytarabine 3Filgrastim 2Cyclophosphamide 2Aprepitant 2Antilymphocyte Serum 2rasburicase 1liposomal amphotericin B 1fludarabine phosphate 1fludarabine 1bosutinib 1blinatumomab 1aldesleukin 1Water 1Voriconazole 1Urate Oxidase 1Tobacco Use Cessation Devices 1Thiotepa 1Rituximab 1Radiotherapy 1Psychiatric Rehabilitation 1Prilocaine 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Pentostatin 1Palonosetron 1Oxygen 1Interleukin-2 1Inotuzumab Ozogamicin 1Histamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia × Histamine × Clear all
NCT01347996 2017-11-29

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia

Cytovia, Inc.

Phase 4 Completed
84 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡